Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
February 20, 2024 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
January 31, 2024 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
December 11, 2023 08:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
November 09, 2023 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis Achieved $1.7 million in net product sales with more than 1,700 dispensed bottles Strengthened...
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
November 01, 2023 18:35 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
September 06, 2023 08:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Present at Upcoming Investor Conferences
August 30, 2023 16:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
August 24, 2023 09:00 ET
|
Tarsus Pharmaceuticals, Inc
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available...
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
August 10, 2023 16:05 ET
|
Tarsus Pharmaceuticals, Inc
XDEMVY™ (lotilaner ophthalmic solution) 0.25% received FDA approval for the treatment for Demodex blepharitis On track to have XDEMVY and sales force in market by the end of August 2023 Completed...
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
August 01, 2023 22:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new...